SpaceX gets FAA approval for 25 Starship launches per year
When you buy through links on our articles, Future and its syndication partners may earn a commission.
SpaceX's Starship vehicle launches on its sixth test flight from Starbase, Texas, on Nov. 19, 2024. | Credit: SpaceX
SpaceX just got permission to ramp up launches of its Starship megarocket from South Texas.
On Tuesday (May 6), the U.S. Federal Aviation Administration (FAA) released its final environmental assessment (EA) of Starship operations at Starbase, the SpaceX facility near Brownsville that just became Texas' newest city.
The report grants SpaceX's request to boost the number of Starship launches from Starbase per year by a factor of five, to 25. It also allows up to 25 landings at the site annually by each of Starship's two stages, the giant booster called Super Heavy and the upper-stage spacecraft known as Starship, or simply Ship.
"After reviewing and analyzing this Final Tiered EA, including all available data and information on existing conditions and potential impacts, the FAA has determined that modifying SpaceX's vehicle operator license supporting the increased launch and landing cadence of the Starship/Super Heavy launch vehicle would not significantly impact the quality of the human environment within the meaning of NEPA," the FAA wrote in a newly released 53-page document called a Mitigated Finding of No Significant Impact (FONSI) and Record of Decision (ROD). (NEPA is the National Environmental Policy Act.)
"Therefore, the preparation of an Environmental Impact Statement is not required, and the FAA is independently issuing this Mitigated FONSI and ROD," it adds.
This finding was hardly a surprise; a draft EA issued by the FAA last November allowed the 25-flight cadence as well.
Related stories:
— SpaceX likely to get FAA approval for 25 Starship launches in 2025
— SpaceX loses Starship rocket stage again, but catches giant Super Heavy booster during Flight 8 launch (video)
— Starship and Super Heavy explained
Starship is the biggest and most powerful rocket ever built, and it's designed to be fully and rapidly reusable. SpaceX and its founder, Elon Musk, believe the giant vehicle will make Mars settlement economically feasible in the not-too-distant future.
Starship has flown eight times to date and twice so far in 2025. Both of this year's test flights, which occurred in January and March, had similar outcomes. Super Heavy performed well, coming back to Starbase for a dramatic catch by the launch tower's "chopstick" arms. But the Ship upper stage had problems, breaking apart less than 10 minutes into flight and raining debris down on the Turks and Caicos Islands and The Bahamas, respectively.
SpaceX is currently gearing up for Starship's ninth flight; it has conducted engine tests with the Super Heavy and Ship that will launch on the upcoming test mission. But we don't know yet when that liftoff will occur.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
See the moon shine with famous red star Antares in the southern sky on June 9
When you buy through links on our articles, Future and its syndication partners may earn a commission. The waxing gibbous moon will shine close to the red star Antares in the constellation Scorpius on the night of June 9. Stargazers in the U.S. will find the moon rising higher over the southeastern horizon after sunset on June 9, with Antares shining brightly around 4 degrees to the lower left of the lunar disk. For context, your little finger held at arms length accounts for roughly 1 degree in the night sky, while your index, middle and ring fingers together amount to around 5 degrees, according to NASA. Antares is also known as the "Heart of the Scorpion" thanks to its prominent position in the zodiacal constellation Scorpius, which itself contains a number of stunning deep sky objects, such as the Messier 4 globular cluster and the closest stellar nursery to Earth — Rho Ophiuchi. As a red supergiant, Antares boasts a diameter 700 times greater than our sun and is known to shine roughly 10,000 times brighter. It is expected to end its life in a dramatic supernova explosion when it runs out of fuel — an event that could happen anytime from tomorrow to a million years or so from now. The lunar disk will appear to close in on Antares as the night of June 9 progresses, with the red star eventually setting above the moon's upper left shoulder as the duo slip beneath the southwestern horizon in the predawn hours of June 10. Viewers based in a number of southern hemisphere countries, including Australia, Tasmania and Papua New Guinea, will see the moon slide directly in front of Antares, blocking its light in an event known as an '"occultation" starting at 4:47 a.m. EDT (0847 GMT), according to Stargazers hoping to capture the majesty of the lunar surface should check out our handy guide detailing how to photograph the moon, while those looking for a closer view of the cosmos should read our lists of the best telescopes and binoculars for exploring the night sky. Editor's Note: If you happen to capture a picture of the moon and Antares and want to share it with readers, then please send your photo(s), comments, and your name and location to spacephotos@
Yahoo
2 hours ago
- Yahoo
HIV/AIDS: Facts about the viral infection that attacks the immune system
When you buy through links on our articles, Future and its syndication partners may earn a commission. QUICK FACTS ABOUT HIV What it is: A lifelong viral infection that weakens the immune system, if left untreated Prevention methods: Taking preventive medicines called PrEP, using condoms, and avoiding needle sharing Treatments: Medicines called antiretroviral therapy (ART) Human immunodeficiency virus (HIV) is a germ that causes a lifelong infection that slowly weakens the immune system. Though the infection is lifelong, medicines can keep the virus in check and help people reach lifespans of near-normal length. However, when people don't have access to those medicines, HIV infections progress to an advanced stage called acquired immunodeficiency syndrome (AIDS), which is fatal within about three years if not treated. When a person has AIDS, most of their key, disease-fighting immune cells are lost. This loss of immune protection leaves the person vulnerable to deadly infections and cancers. Although an HIV diagnosis was once a death sentence, scientists have developed treatments that suppress the virus and enable people to live long lives without transmitting the disease to others. Additionally, there are now effective preventive medications that can dramatically reduce the risk of getting HIV in the first place. There is not yet a widespread cure for HIV/AIDS, although a handful of people have been cured of the infection or are in long-term remission thanks to special stem-cell transplants, specially cell transplants from people who have genes that make them resistant to the virus. Scientists are exploring potential avenues for a cure, which could someday mean that people who contract HIV could be rid of the infection rather than having to take medication for life to manage the disease. HIV/AIDS remains a major public health threat worldwide, with an estimated 39.9 million people living with the disease at the end of 2023. Around 630,000 people died from illnesses related to AIDS the same year; by weakening the immune system, AIDS opens the door to these fatal diseases. HIV can spread through contact with an infected person's bodily fluids, although it's important to note that not all bodily fluids can transmit the virus. Bodily fluids that can spread HIV include blood, semen, preseminal fluid, vaginal secretions, breastmilk and rectal discharge (liquid from the anus that's not blood or stool). HIV is not transmitted through saliva, sweat or tears. It's also not spread through the air or through casual contact, such as hugging, shaking hands or sharing food. For transmission to occur, the bodily fluids containing HIV must come into contact with mucous membranes — tissues that line cavities in the body, like the vagina, anus or mouth. The fluids can also transmit HIV when they come into contact with cuts or sores, or when they're introduced to the bloodstream via contaminated needles, for instance. Most people who contract HIV get it through unprotected anal or vaginal sex — meaning sex without a condom or without HIV-preventing medications. People can also contract the virus by sharing the equipment used to inject drugs, such as needles or syringes. Babies can get HIV in the womb, during childbirth or from breastfeeding, if their mother has HIV. People living with HIV who take medicines called ART can suppress the virus to the point that it can't spread via sex. These "virally suppressed" people also have a much lower chance of transmitting HIV to their kids via pregnancy, childbirth or breastfeeding. They are also less likely to spread the virus via shared injection equipment, although experts aren't sure exactly how much the risk is reduced. The symptoms of HIV vary depending on how far the disease has progressed. The virus can spread from one person to another at any stage of the infection, unless the infected person is taking ART and has reached "viral suppression" (see glossary). The initial stage is called "acute HIV infection." Within two to four weeks of contracting the virus, many people develop a flu-like illness involving symptoms like fever, headache, rash and sore throat. These symptoms can last from a few days to a few weeks. Some people have no symptoms at this stage, however. The viral load, or amount of HIV in the blood, at this stage is very high. The second stage of the disease is "chronic HIV infection," during which the virus continues to multiply but at a slower speed than during acute infection. This stage is also called "clinical latency" or "asymptomatic HIV infection," as many people don't feel sick during it. People can remain in this stage of the disease for 10 to 15 years, though some pass through it more quickly. As the virus multiplies, levels of an important type of immune cell — CD4 T lymphocytes — decline. Without treatment, the disease will eventually enter its most advanced stage: AIDS. This can come with a wide range of symptoms, including rapid weight loss; recurring fever; night sweats; extreme tiredness; prolonged swelling of the lymph nodes; diarrhea; sores of the mouth, anus or genitals; and blotches on or under the skin or inside the mouth, nose or eyelids. It can also trigger neurological problems, like memory loss. AIDS raises the risk of severe bacterial infections and cancers, including lymphomas and Kaposi's sarcoma. It can also worsen viral infections, such as hepatitis B and mpox. Without any treatment, people with AIDS typically survive about three years. HIV and AIDS are related, in that AIDS is the most advanced stage of an HIV infection, and therefore, the HIV virus causes both conditions. AIDS can also be called a "stage 3 HIV infection." AIDS is defined in part by a very low CD4 count of fewer than 200 CD4 cells per cubic millimeter (mm3) of blood. Generally speaking, the CD4 counts of healthy teens and adults are around 500 to 1,200 cells/mm3. Anything below 500 cells/mm3 is considered low, and 200 cells/mm3 marks the threshold for an AIDS diagnosis. Doctors also diagnose AIDS by considering a patient's history of "AIDS-defining illnesses." These are medical conditions often seen in people with AIDS because their immune systems can't fight the illnesses off. They include "opportunistic" infections — those caused by germs that wouldn't necessarily harm a person with a well-functioning immune system. Such infections include a fungal infection called extrapulmonary cryptococcosis, recurrent blood infections with Salmonella bacteria, the parasitic infection toxoplasmosis, and lower respiratory infections caused by the herpes simplex virus. The bacterial disease tuberculosis poses a major risk to people with AIDS, and it is currently the leading cause of death for people living with HIV/AIDS worldwide. AIDS-defining illnesses also include cancers such as Kaposi's sarcoma, Burkitt's lymphoma and invasive cervical cancer. Others include HIV encephalopathy, which affects brain function, and HIV wasting syndrome, which causes extreme weight loss and weakness. Complications of AIDS-defining illnesses raise the risk of death, but the degree of risk varies among diseases. At all three stages of the infection, HIV is treated with antiretroviral therapy (ART) — combinations of medications that drive down the amount of HIV in the blood. Different ART drugs work in different ways to keep the amount of virus, or viral load, in check. They are available as daily pills or as shots given periodically throughout the year, depending on the person's treatment plan. It's key for patients to take their medication as prescribed, because missing pills or shots can open the door for the virus to multiply, as well as develop drug resistance, which causes the medication to work less well. ART medications can also interact with other drugs and carry some risk of serious side effects, so patients work with their medical providers to figure out which drug combination is best for them. The goal of ART is "viral suppression," which describes when a person's viral load falls low enough that there are 200 or fewer copies of the virus's genetic material per milliliter (mL) of blood. Historically, tests weren't sensitive enough to detect levels of HIV below that threshold, so doctors called this level "undetectable." Studies also found that people who reach viral suppression can't transmit the virus via sex; have a lower chance of spreading the virus through pregnancy, childbirth or breastfeeding; and likely have a lower chance of spreading it through needle sharing. This is why the slogan "undetectable equals untransmittable," or "U = U," was coined. Nowadays, some tests for HIV are extremely sensitive, so they can detect viral loads significantly below 200 copies/mL. However, experts emphasize that 200 copies/mL is still the critical threshold at which transmission risk becomes extremely low. If a person with HIV/AIDS develops another medical condition, such as an AIDS-defining illness, the individual would receive treatment for that condition in addition to their ART regimen. There is no widespread cure for HIV/AIDS. However, a handful of people have been cured of their HIV infections through stem cell transplants, and a few more are considered "potentially" cured via the same process. Stem cells can develop into different types of cells in the body. In certain cancers that affect blood cells, stem cell transplants can be used to replace the cells lost in the course of cancer treatments such as chemotherapy. Each individual who has been cured of HIV also had one of these cancers, so their doctors searched for stem cell donors who carry a rare gene that makes them resistant to HIV infection. By swapping in cells from an HIV-resistant individual, the procedure essentially locks the virus out of the patient's CD4 cells. There is one exception to this rule: A person known as the "Geneva patient" was potentially cured of HIV after a stem cell transplant, but the donor didn't have this special genetic resistance. It's unclear exactly why the man entered long-term remission from the infection after this procedure, but scientists are investigating. There have also been a couple of cases in which people's own immune systems somehow rallied against the virus and controlled it without treatment; these people are known as "elite controllers." Scientists hope to learn from both the stem cell recipients and from elite controllers to discover cures that could reach far more people with HIV/AIDS. Meanwhile, some researchers are exploring the use of gene-editing tools like CRISPR to cure the infection, while others are investigating the use of drugs and modified immune cells. Antiretroviral therapy (ART) – Combinations of medications that lower the amount of HIV in a person's blood. These drugs, given as pills or shots, prevent the viral infection from progressing to AIDS and dramatically lower a person's risk of complications and of transmitting the virus to others. Pre-exposure prophylaxis (PrEP) – Medicines that people at risk of being exposed to HIV take to prevent the infection. Viral load – The amount of HIV in a person's blood. This is measured in terms of the number of HIV RNA molecules — the virus's genetic material — found in a milliliter of blood. It's an important way to measure how well ART is working. Viral suppression – When a person's viral load falls to 200 copies/mL or lower. Viral suppression is the goal of ART, as it both lowers a person's likelihood of spreading the virus and extends their lifespan by preventing the infection from progressing to AIDS. CD4 T lymphocyte – A type of white blood cell that helps coordinate the actions of other immune cells to fight infections. HIV infects CD4 cells and uses them to multiply while the virus depletes the number of CD4 cells in the body. Image 1 of 4 In the 1980s and 1990s, groups organized "die-ins" to protest the lack of U.S. government attention to the ongoing HIV/AIDS crisis. Die-ins were also conducted to push for support for research to uncover effective treatments and, once treatments were discovered, to demand that those drugs be released to the public. The AIDS Coalition to Unleash Power — known as ACT UP — was a major force behind such protests and remains an active organization today. Image 2 of 4 Kaposi's sarcoma, an example of an AIDS-defining illness, characteristically causes big, purple patches or nodules to appear on the skin and mucous membranes. Image 3 of 4 The public health slogan "U = U," depicted on this sign, refers to the fact that people living with HIV who have undetectable viral loads cannot transmit the virus to others via sex. It stands for "undetectable = untransmittable." Image 4 of 4 The "Berlin patient," pictured here, was the first person cured of HIV via a stem cell transplant. His name was later revealed to be Timothy Ray Brown. Brown went on to launch a foundation under his name that was dedicated to fighting HIV/AIDS. We could end the AIDS epidemic in less than a decade. Here's how. In a 1st, HIV vaccine triggers rare and elusive antibodies in humans Nearly 3 million extra deaths by 2030 could result from HIV funding cuts, study suggests
Business Insider
3 hours ago
- Business Insider
Tesla (TSLA) Loses $150B as Trump Turns on Musk: What's at Stake for SpaceX and xAI
The public fallout between President Donald Trump and Elon Musk is creating new risks for investors tied to Musk's business empire. The two had a close relationship after the 2024 election, but it unraveled quickly after Musk criticized Trump's tax-and-spending bill. The consequences could impact Tesla (TSLA), SpaceX, and xAI, particularly in areas where federal contracts and political goodwill are involved. Meanwhile, since the family feud began to take shape, TSLA stock is down over 14% in the last five days. Confident Investing Starts Here: Policy Headwinds and Regulatory Risk As stated above, Tesla stock dropped over 14% on Thursday, wiping out about $150 billion in market value in one day. Shares recovered about 4% on Friday, but the damage is a reminder of how sensitive TSLA is to political and regulatory news. Tesla relies on supportive policies for electric vehicles. This includes access to clean energy subsidies, favorable emissions regulations, and potential federal support for autonomous driving. Tesla earns hundreds of millions of dollars each quarter from regulatory credit sales to carmakers that need to meet emissions targets. If Trump follows through on weakening emissions standards, those credits become less valuable. Congress has already voted to eliminate California's right to set stricter emissions rules. That alone could reduce Tesla's credit revenue over time. On autonomy, the situation is also uncertain. Tesla plans to launch its first self-driving taxi service in Austin this month. But federal regulations still lag, and Musk had been pushing for nationwide standards. Losing influence in Washington could slow that progress. SpaceX: Billions in Federal Contracts at Risk SpaceX is deeply connected to the federal government. It launches astronauts for NASA, handles satellite payloads for the Pentagon, and works with the intelligence community. Trump now says he's considering revoking government contracts with Musk's companies. That would hit SpaceX hard. NASA awarded SpaceX contracts worth nearly $5 billion for crewed space station flights. Another $4 billion is earmarked for the Starship moon program. The company also won an $843 million contract to help deorbit the space station. The Department of Defense and National Reconnaissance Office are also customers. In April, SpaceX secured a $5.9 billion contract to launch national security payloads. The NRO has a $1.8 billion classified deal in place as well. Any disruption to these deals could delay missions and create funding gaps. SpaceX is also hoping to participate in the Trump administration's missile-defense program, but that may now be off the table. xAI: Debt Deal Shaken by Political Drama Musk's AI startup xAI is trying to raise $5 billion in debt and $300 million in equity at a $113 billion valuation. Morgan Stanley is leading the deal. Investors had shown interest, but the Trump–Musk feud is creating new concerns. The loans were expected to sell for close to 100 cents on the dollar. But after the feud went public, they dropped to 95 cents, then rebounded to around 97 cents. Morgan Stanley may now need to offer higher interest rates or discounts to complete the deal. The original plan was to sell some of the debt at a 12% rate, which already signaled a high level of risk. xAI is also burning cash. The company posted a Q1 loss of $341 million before interest, taxes, depreciation, and amortization. It expects to break even in the coming years, but rising borrowing costs could extend that timeline. Is Tesla a Buy or Sell Today? According to The Street's analysts, Tesla is Hold, with an average TSLA price target of $285.91. This implies a 3.13% downside. Investable Takeaway This feud introduces a new variable: political risk across Musk's portfolio. Tesla, SpaceX, and xAI all benefit from regulation, federal partnerships, and investor confidence in Musk's ability to work with Washington. If those ties fray, investors may need to rethink how they price these companies. This includes discounting future growth expectations and accounting for higher volatility. For now, Musk-linked assets are under pressure, and the political spotlight isn't fading. Investors will be watching what happens next.
